Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated study of safety, efficacy and tolerability of dutasteride
given for 18 months, including a 1-year double-blind randomized co-administration with either
tolterodine ER or placebo in men suffering from lower urinary tract symptoms (LUTS) including
urgency and frequency, with or without urgency urinary incontinence (i.e., overactive bladder
(OAB) symptoms).